These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 4146729)

  • 1. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.
    Das KM; Eastwood MA; McManus JP; Sircus W
    N Engl J Med; 1973 Sep; 289(10):491-5. PubMed ID: 4146729
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis.
    Collins JR
    South Med J; 1968 Apr; 61(4):354-8. PubMed ID: 4384520
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemolysis during salicylazosulfapyridine therapy.
    van Hees PA; van Elferen LW; van Rossum JM; van Tongeren JH
    Am J Gastroenterol; 1978 Nov; 70(5):501-5. PubMed ID: 33552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the colon in the metabolism of salicylazosulphapyridine.
    Das KM; Eastwood MA; McManus JP; Sircus W
    Scand J Gastroenterol; 1974; 9(2):137-41. PubMed ID: 4150441
    [No Abstract]   [Full Text] [Related]  

  • 5. [Side effects of salicylazosulfapyridine therapy].
    Miller B
    Dtsch Med Wochenschr; 1980 Nov; 105(46):1596-7. PubMed ID: 6108200
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Salozosulphapyridine and its metabolites in ulcerative colitis and Crohn disease].
    Rubinstein BE
    Ugeskr Laeger; 1982 Feb; 144(5):304-6. PubMed ID: 6122297
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: Salicylazosulfapyridine in clinical practice.
    Daz KM
    Gastroenterology; 1974 Feb; 66(2):326. PubMed ID: 4149356
    [No Abstract]   [Full Text] [Related]  

  • 9. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.
    Das KM; Eastwood MA
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):514-20. PubMed ID: 241531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.
    Klotz U; Maier K; Fischer C; Heinkel K
    N Engl J Med; 1980 Dec; 303(26):1499-502. PubMed ID: 6107853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
    Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
    Taffet SL; Das KM
    Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of chronic inflammatory bowel diseases. Clinical aspects and therapy of drug-induced side effects].
    Dölle W; Daiss W
    Verh Dtsch Ges Inn Med; 1988; 94():184-91. PubMed ID: 2905099
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemolytic anemia in patients receiving sulfasalazine.
    Goodacre RL; Ali MA; Vanderlinden B; Hamilton JD; Castelli M; Seaton T
    Digestion; 1978; 17(6):503-8. PubMed ID: 30666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
    Azad Khan AK; Nurazzaman M; Truelove SC
    J Med Genet; 1983 Feb; 20(1):30-6. PubMed ID: 6133000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
    Korelitz BI; Present DH; Rubin PH; Fochios SE
    J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid].
    Malchow H
    Internist (Berl); 1987 Jan; 28(1):14-20. PubMed ID: 2883152
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pulmonary diffusing capacity disorder in nonspecific intestinal inflammations unexplainable by acetylation phenotype or treatment with sulfasalazine].
    Bures J; Horácek J; Tilser P; Fixa B; Komárková O; Tichý M; Zaydlar K; Král B
    Cas Lek Cesk; 1986 Jul; 125(29):905-9. PubMed ID: 2873894
    [No Abstract]   [Full Text] [Related]  

  • 20. Sulfasalazine and new analogues.
    Friedman G
    Am J Gastroenterol; 1986 Feb; 81(2):141-4. PubMed ID: 2868653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.